Filiale de valorisation - Université Grenoble Alpes

Zetaquantor - Post-transplant lymphoproliferative disorder

Screening and early diagnostic test for PTLD

Ref : TO B134

Avantages concurrentiels

  • Serological test
  • Improved care for transplant patients
  • More robust than qPCR analysis of viral load, up to 80% predictivity
  • Simply transferable to clinical laboratories

Opportunités de marché

  • Monitoring of the PTLD status of patients following solid organ or bone marrow transplant
  • Research and preclinical studies
  • Clinical studies

Stade de développement

  • Prototype test, using patented antibodies, is available. 
  • Threshold values established
  • New multi-center retrospective cohort study is underway to confirm the initial results and evaluate the ZEBRA test in the screening for other EBV-linked HSC transplants complications.

=> The project is currently  under maturation process at SATT Linksium


Partenariat recherché

  • Licensing
  • Collaborative research

Propriété intellectuelle

Patent application : WO/2013/083906

Chercheur / Laboratoire

Emmanuel Drouet / Institut de Biologie Structurale (IBS)


Up to 10% of transplanted patients develop a PTLD, Post-transplant lymphoproliferative disorder. This aggressive tumour arises as a result of reactivation of Epstein-Barr virus in a context of immunodepression.

PTLD screening currently involves systematic qPCR testing to detect an increase in Epstein-Barr viral load (EBV). All transplanted patients are screened continuously throughout their lifetimes, at first frequently, and then less frequently over the years if initial results are negative. False-positive and false-negative results have been reported with the qPCR test; it is also incompatible with early diagnosis.

ZETAQUANTOR offers an alternative for PTLD testing, applicable both for screening purposes and for early diagnosis.

Early detection of ZEBRA will allow physicians to adapt the treatment offered to transplant patients by modulating immunosuppressive dose and/or initiating pre-emptive anti-CD20 treatment to directly target tumour cells.

Technology Details

The ZETAQUANTOR test quantifies the key EBV circulating viral protein associated with its lytic cycle – ZEBRA protein – as an indicator of activation of EBV replication. ZEBRA is a toxoid protein involved in tumour progression.

This innovative and simple diagnostic/screening method precisely measures early activation of replication of the EBV and thus provides more precise monitoring of PTLD development in transplant patients than the current reference method. The specificity and response time for ZETAQUANTOR are also better than those of the qPCR method.

The prototype of ZETAQUANTOR for diagnostic, prognostic, and therapeutic monitoring for PTLD measures the soluble ZEBRA protein based on results from an antibody-based ELISA and can be adapted to lateral flow test.


In addition to licensing, the technology is available through collaborative research opportunities with the inventors for further development such as:

  • Adaptation to the lateral flow format
  • Clinical validation in relevant pathologies: HIV, immunosuppression, congenital immune deficiencies but also EBV related deseases mononucleosis, Burkitt's lymphoma, carcinoma of the nasopharynx (NPC), or breast cancer
  • New  antitumor (PTLD) therapy approaches


7 Allée Palestine
38610 Gières

Tél : +33 (0)4 56 52 04 30

E-mail : contact@floralis.fr


Inscription à la Newletter

Nous utilisons des cookies pour vous garantir la meilleure expérience sur notre site. Si vous continuez à utiliser ce dernier, nous considérerons que vous acceptez l'utilisation des cookies. En savoir plus OK